Xynomic Forms Partnership with UCSF for Cancer Drug Trial

Xynomic Pharma, a US-China oncology startup, entered a strategic partnership with the University of California San Francisco to conduct a Phase II/III clinical trial of its lead drug, abexinostat. Abexinostat is an HDAC inhibitor that is designed to overcome chemotherapy resistance, and Xynomic expects it will prove to be best-in-class. The company in-licensed global rights to abexinostat from AbbVie three months ago. Headquartered in Cheyenne, Wyoming, Xynomic also has operations in China. More details.... Stock Symbol: (NYSE: ABBV) Share this with colleagues: // //